Takeda's Senior VP Joins Dementia Discovery Fund
This article was originally published in Scrip
The Dementia Discovery Fund (DDF), a global investment fund managed by SV Life Sciences, has appointed Tetsuyuki Maruyama chief scientific officer – effective April, 2016. Maruyama joins DDF from Takeda Pharmaceutical Co. Ltd. where he was senior vice president, general manager, pharmaceutical research division for the past five years. Prior to, this he was director of GlaxoSmithKline Plc's neuroscience research centre in Singapore and led Alzheimer's disease target discovery efforts at Merck Sharpe & Dohme, Ltd.